Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics is actively working on developing a strong pipeline of products focused on metabolic and endocrine disorders, which creates a positive outlook for the company's growth potential in the long term. Furthermore, Viking's partnerships with LGND to gain access to patented compounds and its strategy of single molecule, multi-format for its drugs, highlight the company's strong focus on innovation and differentiation in the market. Lastly, the company's management has made deliberate efforts to address potential challenges in its manufacturing and supply chain, which could provide a competitive advantage for the company in the future.

Viking Therapeutics is facing serious headwinds as its major collaboration with Ligand Pharmaceuticals has been terminated due to a material breach of obligation. This collaboration was a key driver of Viking's pipeline, including VK2809 and VK0214, and the loss of this support may significantly delay the progress of its clinical programs. Additionally, the company's cash balance will be worth monitoring as Phase 3 data for VK2735 is expected in 2027. Overall, there may be significant challenges in terms of funding and timeline for Viking's clinical development and commercialization efforts, which could have a negative impact on the company's financials and investor sentiment.